NCT00514046View on ClinicalTrials.gov

Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 20, 2007

Primary Completion Date

December 10, 2019

Study Completion Date

November 1, 2020

Conditions
Medullary Thyroid CarcinomaMultiple Endocrine Neoplasia Type 2AMultiple Endocrine Neoplasia Type 2B
Interventions
DRUG

Vandetanib

once daily continuously (28 day cycles)

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00514046 - Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer | Biotech Hunter | Biotech Hunter